Contact Us
Drug Search Results
More Filters [+]

mRNA-6231

Alternative Names: mrna-6231, mrna6231, mrna 6231
Latest Update: 2022-08-10
Latest Update Note: Clinical Trial Update

Product Description

mRNA‑6231 is a lipid nanoparticle (LNP)‑encapsulated mRNA-based therapeutic that encodes for mutein human interleukin 2, fused to human serum albumin (HSA‑IL2m), with the goal of achieving enhanced selectivity toward T regulatory cells. IL-2 through preferential expansion of Tregs is hypothesized to play a central role in restoring immune homeostasis. (Sourced from: https://investors.modernatx.com/news/news-details/2021/Moderna-Announces-First-Participant-Dosed-in-Phase-1-Study-of-Its-IL-2-mRNA-Therapeutic/default.aspx)

Mechanisms of Action: IL2 Agonist

Novel Mechanism: Yes

Modality: Nucleic Acid

Route of Administration: Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Moderna
Company Location: CAMBRIDGE MA 02139
Company CEO: Stéphane Bancel
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for mRNA-6231

Countries in Clinic: Australia

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Autoimmune Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
mRNA-6231-P101

P1

Completed

Autoimmune Diseases

2022-08-02

Recent News Events

Date

Type

Title

11/04/2021

News Article

 Moderna Reports Third Quarter Fiscal Year 2021 Financial Results and Provides Business Updates

08/05/2021

News Article

 Moderna Reports Second Quarter Fiscal Year 2021 Financial Results and Provides Business Updates

08/02/2021

News Article

 Moderna Announces First Participant Dosed in Phase 1 Study of Its IL-2 mRNA Therapeutic

05/06/2021

News Article

 Moderna Reports First Quarter Fiscal Year 2021 Financial Results and Provides Business Updates

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions